Tricida Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$257M
Industry:Pharma
Founded:2013
Lead Investor(s):Hercules Capital
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Tricida's estimated revenue is currently $10.9M per year.
  • Tricida received $100.0M in venture funding in March 2018.
  • Tricida's estimated revenue per employee is $106412
  • Tricida's total funding is $257M.

Employee Data

  • Tricida has 102 Employees.
  • Tricida grew their employee count by 34% last year.
  • Tricida currently has 19 job openings.

Executive Contacts

NameTitle
Geoffrey ParkerChief Financial Officer and Senior Vice President
Matt FordVice President Human Resources
Gerrit KlaernerCEO/President
Wolfgang SchmidtVice President CMC Development and Supply Chain Management
Uni BuckleyExecutive Assistant to the President/CEO
Thomas KoberDirector of FP&A
Brittney ElkoAssociate Director Clinical Supply Chain
David SkidmoreDirector, Quality Assurance
Paul KiersteadDirector, Drug Substance Manufacturing
Edward HejlekGeneral Counsel & SVP

What Is Tricida?

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its late-stage investigational product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. We recently completed a successful Initial Public Offering and our stock is listed on the Nasdaq Global Select Market under the symbol TCDA. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101. Tricida's shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients. Highly Competitive Compensation and Benefits

keywords:Analytics,Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

102

Number of Employees

$10.9M

Revenue (est)

19

Current Jobs

34%

Employee Growth %

$257M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
$12.3M653%
Rancho BioScien...
$10.1M5423%
Tlc Pharmacy
$8M435%
Otsuka America
$10.7M5719%
endpoint Clinic...
$55.9M29710%
GCAM
$17.9M954%
ZO Skin Health
$55.5M2952%
Teledyne Hanson...
$8.4M4515%
VIVUS
$19.3M1038%
AmeriPharma
$8.4M455%

Tricida News

09/03/2019 - Tricida Announces Submission of New Drug Application for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. NDA Submitted under the FDA's Accelerated Approval Program. Tricida, Inc. (TCDA), a ...

09/04/2019 - Tricida (TCDA) Announces Submission of New Drug ...

Tricida (TCDA) Announces Submission of New Drug Application for Veverimer for Treatment of Metabolic Acidosis in Patients with CKD.

09/03/2019 - Claire Lockey Sells 10000 Shares of Tricida Inc (NASDAQ ...

Tricida Inc (NASDAQ:TCDA) VP Claire Lockey sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd.

Tricida Funding

DateAmountRoundLead InvestorsReference
2014-02-03$4.5MUndisclosedArticle
2015-03-05$30.0MBOrbiMedArticle
2016-07-26$55.0MCLongitude CapitalArticle
2017-11-09$57.5MDWellington Management Company LLPArticle
2018-03-05$100.0MUndisclosedHercules CapitalArticle

Tricida Executive Hires

DateNameTitleReference
2016-01-13Claire LockeyChief Development Officer/SVPArticle
2017-02-16Wilhelm StahlSVP/Chief Technology OfficerArticle
2017-04-12Geoffrey ParkerSVP/CFOArticle
2018-01-09Jeroen van BeekSVP & Chief Commercial OfficerArticle
2018-08-02Dawn ParsellSVP Clinical DevelopmentArticle
2019-01-18Susannah CantrellSVP/Chief Commercial OfficerArticle